SynthesisBMC cancer2023

PD-1/PD-L1 inhibitors plus carboplatin and paclitaxel compared with carboplatin and paclitaxel in primary advanced or recurrent endometrial cancer: a systematic review and meta-analysis of randomized clinical trials.

Francisco Cezar Aquino de Moraes et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.